SK472001A3 - Use of bisphosphonates in the treatment of vascular restenosis - Google Patents

Use of bisphosphonates in the treatment of vascular restenosis Download PDF

Info

Publication number: SK472001A3
Authority: SK; Slovakia
Prior art keywords: active ingredient; restenosis; pharmaceutical composition; particles; clodronate
Prior art date: 1998-07-14

Application number

SK47-2001A

Other languages

English (en)

Slovak (sk)

Inventor

Gershon Golomb

Haim Daneberg

Original Assignee

Yissum Res Dev Co

Hadasit Med Res Service

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-14

Filing date

1999-07-14

Publication date

2001-09-11

1999-07-14 Application filed by Yissum Res Dev Co, Hadasit Med Res Service filed Critical Yissum Res Dev Co

2001-09-11 Publication of SK472001A3 publication Critical patent/SK472001A3/sk

Links

208000037803 restenosis Diseases 0.000 title claims abstract description 35
229940122361 Bisphosphonate Drugs 0.000 title claims abstract description 33
150000004663 bisphosphonates Chemical class 0.000 title claims abstract description 32
238000011282 treatment Methods 0.000 title claims abstract description 27
230000002792 vascular Effects 0.000 title claims abstract description 9
235000011180 diphosphates Nutrition 0.000 claims abstract description 12
229920000642 polymer Polymers 0.000 claims abstract description 12
150000003839 salts Chemical class 0.000 claims abstract description 12
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims abstract description 8
230000002265 prevention Effects 0.000 claims abstract description 8
239000004480 active ingredient Substances 0.000 claims description 46
239000002502 liposome Substances 0.000 claims description 44
229960002286 clodronic acid Drugs 0.000 claims description 32
ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 31
238000000034 method Methods 0.000 claims description 23
239000002245 particle Substances 0.000 claims description 21
239000000203 mixture Substances 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 14
125000001072 heteroaryl group Chemical group 0.000 claims description 9
229910052736 halogen Inorganic materials 0.000 claims description 8
150000002367 halogens Chemical class 0.000 claims description 8
238000002360 preparation method Methods 0.000 claims description 8
238000007920 subcutaneous administration Methods 0.000 claims description 8
125000003277 amino group Chemical group 0.000 claims description 5
125000003118 aryl group Chemical group 0.000 claims description 5
229910052739 hydrogen Inorganic materials 0.000 claims description 5
150000002431 hydrogen Chemical group 0.000 claims description 5
239000001257 hydrogen Substances 0.000 claims description 5
125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 4
201000000054 Coronary Restenosis Diseases 0.000 claims description 4
206010056489 Coronary artery restenosis Diseases 0.000 claims description 4
DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 4
DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
125000001309 chloro group Chemical group Cl* 0.000 claims description 4
125000006310 cycloalkyl amino group Chemical group 0.000 claims description 4
229940009626 etidronate Drugs 0.000 claims description 4
125000000623 heterocyclic group Chemical group 0.000 claims description 4
238000007918 intramuscular administration Methods 0.000 claims description 4
238000001990 intravenous administration Methods 0.000 claims description 4
WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims description 4
229940046231 pamidronate Drugs 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
125000004076 pyridyl group Chemical group 0.000 claims description 4
229940019375 tiludronate Drugs 0.000 claims description 4
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
125000003282 alkyl amino group Chemical group 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
238000010348 incorporation Methods 0.000 claims description 2
206010051113 Arterial restenosis Diseases 0.000 claims 1
238000007911 parenteral administration Methods 0.000 claims 1
150000002148 esters Chemical class 0.000 abstract description 5
241000700159 Rattus Species 0.000 description 22
239000013543 active substance Substances 0.000 description 19
230000000694 effects Effects 0.000 description 17
238000002399 angioplasty Methods 0.000 description 16
208000031481 Pathologic Constriction Diseases 0.000 description 12
230000036262 stenosis Effects 0.000 description 12
208000037804 stenosis Diseases 0.000 description 12
208000034827 Neointima Diseases 0.000 description 10
208000027418 Wounds and injury Diseases 0.000 description 10
230000006378 damage Effects 0.000 description 10
210000001367 artery Anatomy 0.000 description 9
208000014674 injury Diseases 0.000 description 9
210000000988 bone and bone Anatomy 0.000 description 8
239000000243 solution Substances 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
238000002347 injection Methods 0.000 description 7
239000007924 injection Substances 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 5
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
238000000576 coating method Methods 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
230000008692 neointimal formation Effects 0.000 description 5
230000009885 systemic effect Effects 0.000 description 5
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
238000011552 rat model Methods 0.000 description 4
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
238000010171 animal model Methods 0.000 description 3
230000003143 atherosclerotic effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
230000002308 calcification Effects 0.000 description 3
-1 clodronate compound Chemical class 0.000 description 3
210000004351 coronary vessel Anatomy 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000011555 rabbit model Methods 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000009576 somatic growth Effects 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
108010002352 Interleukin-1 Proteins 0.000 description 2
FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 description 2
229920005654 Sephadex Polymers 0.000 description 2
239000012507 Sephadex™ Substances 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000024279 bone resorption Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
210000000269 carotid artery external Anatomy 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
235000012000 cholesterol Nutrition 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000003902 lesion Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
239000000178 monomer Substances 0.000 description 2
238000007491 morphometric analysis Methods 0.000 description 2
230000011164 ossification Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
210000003752 saphenous vein Anatomy 0.000 description 2
230000028327 secretion Effects 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
210000000329 smooth muscle myocyte Anatomy 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000011285 therapeutic regimen Methods 0.000 description 2
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010003162 Arterial injury Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000006386 Bone Resorption Diseases 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
102000016942 Elastin Human genes 0.000 description 1
108010014258 Elastin Proteins 0.000 description 1
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
208000035150 Hypercholesterolemia Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
208000010191 Osteitis Deformans Diseases 0.000 description 1
208000003076 Osteolysis Diseases 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
208000027868 Paget disease Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
ICTZKEXYDDZZFP-SRVKXCTJSA-N Pro-Arg-Pro Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 ICTZKEXYDDZZFP-SRVKXCTJSA-N 0.000 description 1
241000452413 Sabra Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
206010057469 Vascular stenosis Diseases 0.000 description 1
ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
238000002679 ablation Methods 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
238000003975 animal breeding Methods 0.000 description 1
230000002272 anti-calculus Effects 0.000 description 1
230000000733 anti-osteolytic effect Effects 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
210000001168 carotid artery common Anatomy 0.000 description 1
238000013172 carotid endarterectomy Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
230000010339 dilation Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000002224 dissection Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
229920002549 elastin Polymers 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000001125 extrusion Methods 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000000834 fixative Substances 0.000 description 1
239000008098 formaldehyde solution Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000002695 general anesthesia Methods 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000012735 histological processing Methods 0.000 description 1
208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
238000002513 implantation Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000000608 laser ablation Methods 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
208000029791 lytic metastatic bone lesion Diseases 0.000 description 1
230000013227 macrophage apoptotic process Effects 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
208000027202 mammary Paget disease Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
239000002088 nanocapsule Substances 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
150000004027 organic amino compounds Chemical class 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000001151 other effect Effects 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
230000000242 pagocytic effect Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000037368 penetrate the skin Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
210000001539 phagocyte Anatomy 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000000250 revascularization Effects 0.000 description 1
210000005241 right ventricle Anatomy 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000008719 thickening Effects 0.000 description 1
239000000606 toothpaste Substances 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Mechanical Treatment Of Semiconductor (AREA)
Saccharide Compounds (AREA)
Materials For Medical Uses (AREA)
Medicines Containing Plant Substances (AREA)
Steroid Compounds (AREA)

SK47-2001A 1998-07-14 1999-07-14 Use of bisphosphonates in the treatment of vascular restenosis SK472001A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL12533698A IL125336A0 (en)	1998-07-14	1998-07-14	Compositions for inhibition and treatment of restinosis
PCT/IL1999/000387 WO2000003677A2 (fr)	1998-07-14	1999-07-14	Traitement de la restenose

Publications (1)

Publication Number	Publication Date
SK472001A3 true SK472001A3 (en)	2001-09-11

Family

ID=11071743

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK47-2001A SK472001A3 (en)	1998-07-14	1999-07-14	Use of bisphosphonates in the treatment of vascular restenosis

Country Status (17)

Country	Link
US (1)	US6719998B1 (fr)
EP (2)	EP1468691B1 (fr)
JP (4)	JP4663116B2 (fr)
KR (1)	KR20010074711A (fr)
CN (1)	CN1321090A (fr)
AT (2)	ATE262338T1 (fr)
AU (1)	AU758882B2 (fr)
BR (1)	BR9912066A (fr)
CA (1)	CA2337175C (fr)
DE (2)	DE69915834T2 (fr)
EE (1)	EE200100025A (fr)
ES (2)	ES2219028T3 (fr)
IL (3)	IL125336A0 (fr)
NO (1)	NO20010224L (fr)
PL (1)	PL345782A1 (fr)
SK (1)	SK472001A3 (fr)
WO (1)	WO2000003677A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL125336A0 (en) *	1998-07-14	1999-03-12	Yissum Res Dev Co	Compositions for inhibition and treatment of restinosis
US7008645B2 (en) *	1998-07-14	2006-03-07	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Method of inhibiting restenosis using bisphosphonates
KR100763064B1 (ko) *	1999-05-21	2007-10-04	노파르티스 아게	제약 조성물 및 용도
EP1267888A4 (fr) *	2000-01-04	2005-12-28	Univ California	Utilisation de bisphosphonates a faible dose pour inhiber la calcification cardiaque et arterielle
EP1372753B1 (fr) *	2001-02-16	2007-08-01	Abbott Laboratories Vascular Enterprises Limited	Implants avec fk506 pour la prophylaxie et le traitement de la restenose
US6656506B1 (en) *	2001-05-09	2003-12-02	Advanced Cardiovascular Systems, Inc.	Microparticle coated medical device
JP2006504749A (ja) *	2002-10-15	2006-02-09	ノバルティスアクチエンゲゼルシャフト	アテローム性動脈硬化症の処置のためのビスホスホネートおよびそれらを含むデバイス
US8034361B2 (en) *	2002-11-12	2011-10-11	Advanced Cardiovascular Systems, Inc.	Stent coatings incorporating nanoparticles
US10517883B2 (en) *	2003-06-27	2019-12-31	Zuli Holdings Ltd.	Method of treating acute myocardial infarction
US20060051407A1 (en) *	2003-06-27	2006-03-09	Yoram Richter	Method of treating ischemia-reperfusion injury
WO2005002545A1 (fr) *	2003-06-27	2005-01-13	Biorest Ltd.	Procede de traitement du syndrome coronarien aigu
US20050153937A1 (en) *	2003-11-07	2005-07-14	Gershon Golomb	Desensitization of compliment activation using monocyte/macrophage inhibitory compounds
CN100364544C (zh) *	2004-07-21	2008-01-30	上海第二医科大学附属瑞金医院	一种携带二氯亚甲基二膦酸的明胶微粒及制备方法
US7687482B2 (en)	2006-03-17	2010-03-30	The Board Of Trustees Of The University Of Illinois	Bisphosphonate compounds and methods
US7358361B2 (en)	2004-10-08	2008-04-15	The Board Of Trustees Of The University Of Illinois	Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2008128056A1 (fr)	2004-10-08	2008-10-23	The Board Of Trustees Of The University Of Illinois	Composés bisphosphonates et procédés présentant un potentiel amélioré pour cibles multiples incluant fpps, ggpps, et dpps
WO2006087722A1 (fr) *	2005-02-17	2006-08-24	Hadasit Medical Research Services And Development Ltd.	Bisphosphonates pour le traitement de l'endometriose
BRPI0606280A2 (pt) *	2005-03-17	2009-06-09	Elan Pharma Int Ltd	composições de bisfosfonato nanoparticulado
US20080181928A1 (en) *	2006-12-22	2008-07-31	Miv Therapeutics, Inc.	Coatings for implantable medical devices for liposome delivery
US8802184B2 (en)	2007-05-30	2014-08-12	Abbott Cardiovascular Systems Inc.	Medical devices containing biobeneficial particles
US20090099651A1 (en) *	2007-10-10	2009-04-16	Miv Therapeutics, Inc.	Lipid coatings for implantable medical devices
US20090148491A1 (en) *	2007-12-05	2009-06-11	Abbott Cardiovascular Systems Inc.	Dual-Targeted Drug Carriers
EP2255199A1 (fr) *	2008-02-19	2010-12-01	Jovesis Inc.	Compositions de microparticules pour modifier des cellules favorisant le cancer
BRPI0915885A2 (pt) *	2008-07-09	2015-11-03	Univ Nebraska	micelas funcionais para a liberação direcionada de substâncias químicas em tecido duro
US20130315981A1 (en) *	2010-06-25	2013-11-28	The Trustees Of Columbia University In The City Of New York	Method for inducing fat loss in mammals
GB201200868D0 (en) *	2012-01-19	2012-02-29	Depuy Int Ltd	Bone filler composition
EP2769741A1 (fr) *	2013-02-22	2014-08-27	Cardiatis S.A.	Dispositif médical avec un revêtement biocompatible
US9993427B2 (en)	2013-03-14	2018-06-12	Biorest Ltd.	Liposome formulation and manufacture
AU2015258964B2 (en)	2014-05-16	2018-01-04	Oregon Health And Science University	Use of bisphosphonates as HIV/AIDS adjunctive treatment
JP6910033B2 (ja) *	2016-08-01	2021-07-28	株式会社カネカ	カルシプロテインパーティクルの吸着材、および吸着除去システムとその利用方法
CN106361701B (zh) *	2016-08-31	2019-08-27	上海交通大学	一种脂质体药物载体及其制备方法和应用
FR3068233A1 (fr) *	2017-07-03	2019-01-04	Omnium De Revalorisation Industrielle Odri	Dispositif medical intra-arteriel et applications
JP6613290B2 (ja)	2017-11-28	2019-11-27	株式会社Ｓｕｂａｒｕ	運転アドバイス装置及び運転アドバイス方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4067971A (en)	1976-05-13	1978-01-10	The Procter & Gamble Company	Therapeutic composition
US4216211A (en)	1977-10-31	1980-08-05	The Procter & Gamble Company	Therapeutic composition
WO1988000289A1 (fr)	1986-07-09	1988-01-14	Engine Technology Limited	Segment de piston
CH675422A5 (fr) *	1988-03-31	1990-09-28	Symphar Sa
US5196409A (en)	1989-08-20	1993-03-23	Yissum, Research Development Company Of The Hebrew University Of Jerusalem	Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
IL91362A0 (en)	1989-08-20	1990-03-19	Yissum Res Dev Co	Bisphosphonates,process for preparing them and pharmaceutical compositions containing them
PH27186A (en)	1989-09-07	1993-04-16	Ciba Geigy Ag	Double-coated granules of disodium pamidronate
CA2042159A1 (fr)	1990-05-31	1991-12-01	Miguel A. Ondetti	Methode de prevention de la restenose apres angioplastie faisant appel a un inhibiteur de l'enzyme de conversion de l'angiotensine
CA2124857A1 (fr) *	1991-11-11	1993-05-27	Howard C. Herrmann	Methodes d'inhibition de la restenose
US5358941A (en)	1992-12-02	1994-10-25	Merck & Co., Inc.	Dry mix formulation for bisphosphonic acids with lactose
FI92465C (fi)	1993-04-14	1994-11-25	Risto Tapani Lehtinen	Menetelmä endo-osteaalisten materiaalien käsittelemiseksi
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
US5457113A (en) *	1993-10-15	1995-10-10	Eli Lilly And Company	Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
ATE252894T1 (de) *	1995-01-05	2003-11-15	Univ Michigan	Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
US5652227A (en)	1995-01-30	1997-07-29	Teronen; Olli Pekka	Inhibition of the degradation of connective tissue matrix protein components in mammals
US5741514A (en) *	1995-08-31	1998-04-21	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Method for reducing serum lipoprotein(a) concentration
CN1304058C (zh) *	1996-03-12	2007-03-14	Pg－Txl有限公司	水溶性紫杉醇产品
WO1997043437A2 (fr) *	1996-05-15	1997-11-20	The University Of Sheffield	Inhibiteurs d'isopentenyle pyrophosphate isomerase (ipi) ou de prenyle transferase
KR100192215B1 (ko)	1996-09-03	1999-06-15	강재헌	3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
JP2001509176A (ja) *	1997-01-17	2001-07-10	メルクエンドカンパニーインコーポレーテッド	インテグリンアンタゴニスト
US5760030A (en)	1997-06-30	1998-06-02	Eli Lilly And Company	Benzothiophene compounds and methods of use
US5932580A (en)	1997-12-01	1999-08-03	Yissum Research And Development Company Of The Hebrew University Of Jerusalem	PDGF receptor kinase inhibitory compounds their preparation and compositions
AU760703B2 (en) *	1998-01-29	2003-05-22	Merck & Co., Inc.	Methods of identifying modulators of kinases responsive to stress
IL125336A0 (en) *	1998-07-14	1999-03-12	Yissum Res Dev Co	Compositions for inhibition and treatment of restinosis
EP0998932A1 (fr)	1998-10-09	2000-05-10	Boehringer Mannheim Gmbh	Forme d'administration pharmaceutique contenant des diphosphonates ou leurs sels et méthode pour la fabriquer
US5932563A (en)	1998-10-23	1999-08-03	Ohio State Research Foundation	Methods for treating spinal cord injury
EP1135397B1 (fr)	1998-12-10	2003-04-23	Aesgen, Inc.	Methode de preparation du pamidronate de disodium
EP1210138A4 (fr)	1999-04-22	2003-05-07	Hydro Med Sciences Inc	Administration regulee de bisphosphonates

1998
- 1998-07-14 IL IL12533698A patent/IL125336A0/xx unknown
1999
- 1999-07-14 AT AT99929687T patent/ATE262338T1/de not_active IP Right Cessation
- 1999-07-14 PL PL99345782A patent/PL345782A1/xx unknown
- 1999-07-14 EE EEP200100025A patent/EE200100025A/xx unknown
- 1999-07-14 KR KR1020017000569A patent/KR20010074711A/ko not_active Withdrawn
- 1999-07-14 JP JP2000559812A patent/JP4663116B2/ja not_active Expired - Lifetime
- 1999-07-14 SK SK47-2001A patent/SK472001A3/sk unknown
- 1999-07-14 DE DE69915834T patent/DE69915834T2/de not_active Expired - Lifetime
- 1999-07-14 WO PCT/IL1999/000387 patent/WO2000003677A2/fr not_active Ceased
- 1999-07-14 CN CN99810638A patent/CN1321090A/zh active Pending
- 1999-07-14 DE DE69942510T patent/DE69942510D1/de not_active Expired - Lifetime
- 1999-07-14 EP EP04006854A patent/EP1468691B1/fr not_active Expired - Lifetime
- 1999-07-14 ES ES99929687T patent/ES2219028T3/es not_active Expired - Lifetime
- 1999-07-14 ES ES04006854T patent/ES2347553T3/es not_active Expired - Lifetime
- 1999-07-14 EP EP99929687A patent/EP1094820B1/fr not_active Expired - Lifetime
- 1999-07-14 AU AU46462/99A patent/AU758882B2/en not_active Expired
- 1999-07-14 AT AT04006854T patent/ATE471149T1/de not_active IP Right Cessation
- 1999-07-14 IL IL14217299A patent/IL142172A0/xx active IP Right Grant
- 1999-07-14 BR BR9912066-6A patent/BR9912066A/pt not_active IP Right Cessation
- 1999-07-14 CA CA002337175A patent/CA2337175C/fr not_active Expired - Lifetime
- 1999-07-14 US US09/743,705 patent/US6719998B1/en not_active Expired - Lifetime
2001
- 2001-01-12 NO NO20010224A patent/NO20010224L/no unknown
- 2001-03-21 IL IL142172A patent/IL142172A/en not_active IP Right Cessation
2010
- 2010-10-01 JP JP2010223610A patent/JP5498342B2/ja not_active Expired - Lifetime
2013
- 2013-08-22 JP JP2013172443A patent/JP5903081B2/ja not_active Expired - Lifetime
2015
- 2015-10-19 JP JP2015205518A patent/JP6088619B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP4663116B2 (ja)	2011-03-30
US6719998B1 (en)	2004-04-13
JP2011037871A (ja)	2011-02-24
JP2016041724A (ja)	2016-03-31
DE69942510D1 (de)	2010-07-29
JP5498342B2 (ja)	2014-05-21
IL142172A (en)	2007-07-24
EP1094820A2 (fr)	2001-05-02
KR20010074711A (ko)	2001-08-09
CA2337175C (fr)	2009-03-31
NO20010224D0 (no)	2001-01-12
NO20010224L (no)	2001-03-09
JP5903081B2 (ja)	2016-04-13
EP1468691A1 (fr)	2004-10-20
EE200100025A (et)	2002-06-17
PL345782A1 (en)	2002-01-02
EP1468691B1 (fr)	2010-06-16
AU758882B2 (en)	2003-04-03
ATE471149T1 (de)	2010-07-15
CA2337175A1 (fr)	2000-01-27
EP1094820B1 (fr)	2004-03-24
DE69915834T2 (de)	2005-03-24
AU4646299A (en)	2000-02-07
JP2002520345A (ja)	2002-07-09
ATE262338T1 (de)	2004-04-15
JP6088619B2 (ja)	2017-03-01
DE69915834D1 (de)	2004-04-29
BR9912066A (pt)	2001-04-10
WO2000003677A2 (fr)	2000-01-27
WO2000003677A3 (fr)	2000-05-04
IL142172A0 (en)	2002-03-10
IL125336A0 (en)	1999-03-12
JP2013256524A (ja)	2013-12-26
ES2347553T3 (es)	2010-11-02
CN1321090A (zh)	2001-11-07
ES2219028T3 (es)	2004-11-16

Publication	Publication Date	Title
SK472001A3 (en)	2001-09-11	Use of bisphosphonates in the treatment of vascular restenosis
US6984400B2 (en)	2006-01-10	Method of treating restenosis using bisphosphonate nanoparticles
US7008645B2 (en)	2006-03-07	Method of inhibiting restenosis using bisphosphonates
ES2753883T3 (es)	2020-04-14	Composición para su uso en un método de tratamiento de la hiperplasia
US4216211A (en)	1980-08-05	Therapeutic composition
US4067971A (en)	1978-01-10	Therapeutic composition
JP2003519183A (ja)	2003-06-17	心臓および動脈の石灰化を抑制する低用量ビスホスホネートの使用
JPH08502728A (ja)	1996-03-26	抗増殖オリゴマー類
CZ2001104A3 (cs)	2001-07-11	Způsob léčení restenosy
JP2007510711A (ja)	2007-04-26	単球／マクロファージ阻害化合物を用いる補体活性化の脱感作
MXPA01000431A (en)	2002-07-25	Treatment of restenosis
US20060166937A1 (en)	2006-07-27	Bisphosphonates for the treatment of atherosclerosis and device comprising them
US8748410B2 (en)	2014-06-10	Methods of treating aneurysm
US20050261756A1 (en)	2005-11-24	Coated stent
US20070149505A1 (en)	2007-06-28	Method of Inhibiting Adhesion Formation